-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 12, TusHoldings issued an announcement stating that the company held the fourth meeting of the Ninth Board of Directors on August 26, 2021, at which the "Proposal on the Proposal to Cancel Some Wholly Owned Subsidiaries" was reviewed and approved, and it was agreed that the company plans to cancel its wholly-owned subsidiaries.
Subsidiaries "Hunan Guhan Biological Technology Co.
, Ltd.
" and "Hengyang Qidi Guhan Industrial Park Development Co.
, Ltd.
"
.
Since neither of the above two companies has carried out actual business operations, the cancellation will not have a substantial impact on the company's financial status, nor will it have a significant adverse impact on the company's overall business development and profitability
.
Coincidentally, Jinling Pharmaceutical also recently issued an announcement stating that the company reviewed and approved the "Proposal on Canceling Branches" at the eleventh meeting of the Eighth Board of Directors held on September 28
.
Agree to cancel Jinling Pharmaceutical Co.
, Ltd.
Nanjing Jinwei Health Products Branch (hereinafter referred to as "Jinwei Company"), and authorize the company's management to be responsible for the cancellation and other related matters
.
It is understood that Jinling Pharmaceutical’s cancellation of Jinwei Company is based on the overall strategic planning considerations, which will help further integrate the company's resources, improve the company's management efficiency, and reduce management costs
.
It is worth noting that according to incomplete statistics, since this year, at least 20 domestic pharmaceutical companies have announced the sale of shares, subsidiaries, and divestiture of core businesses, including Fosun Pharma, Zhendong Pharmaceutical, and Beike Biotech
.
For example, on August 31, Guangdong Dongyangguang issued an announcement to transfer the company’s holding of no more than 51.
41% equity in Yichang Dongyangyang Yangtze River Pharmaceutical Co.
, Ltd.
After the transfer, Dongyangguang will divest the entire pharmaceutical sector
.
On August 17, Zhendong Pharmaceutical and Shanghai Fanglang signed the "Equity Sale Agreement" and also decided to sell 100% of the wholly-owned subsidiary Langdi Pharmaceuticals to Shanghai Fanglang at a price of 5.
8 billion yuan
.
In this regard, industry analysts believe that behind the frequent subtraction of pharmaceutical companies, it is actually affected by the national policy to encourage the development of innovative drugs, the consistency evaluation of generic drugs, and the large-scale procurement of pharmaceuticals
.
In fact, in recent years, a large number of pharmaceutical companies have been accelerating reform and development by selling shares, subsidiaries, and divesting their core businesses.
.
In this regard, industry analysts believe that under the background of rapid iteration in the pharmaceutical industry, bankruptcies, write-offs, and sales of enterprises have become the norm
.
In the future, in order to make the corporate strategy more focused, more and more companies will sell their assets that are not in line with their own strategic development, so as to focus on the development of the company's main business
.
In general, with a series of industrial upgrades guided by pharmaceutical policies, it is an inevitable event that some companies are left behind and eliminated passively or actively
.
For pharmaceutical companies, under centralized procurement, pharmaceutical profit margins are compressed, prices are squeezed out, and the industry structure has changed
.
If pharmaceutical companies cannot make changes with the changes in the pharmaceutical market, then companies will face elimination
.
In the future, competition in the pharmaceutical market is destined to become more and more fierce, and companies can only occupy a place on the pharmaceutical stage for a long time only if they are both internal and external
.
Subsidiaries "Hunan Guhan Biological Technology Co.
, Ltd.
" and "Hengyang Qidi Guhan Industrial Park Development Co.
, Ltd.
"
.
Since neither of the above two companies has carried out actual business operations, the cancellation will not have a substantial impact on the company's financial status, nor will it have a significant adverse impact on the company's overall business development and profitability
.
Coincidentally, Jinling Pharmaceutical also recently issued an announcement stating that the company reviewed and approved the "Proposal on Canceling Branches" at the eleventh meeting of the Eighth Board of Directors held on September 28
.
Agree to cancel Jinling Pharmaceutical Co.
, Ltd.
Nanjing Jinwei Health Products Branch (hereinafter referred to as "Jinwei Company"), and authorize the company's management to be responsible for the cancellation and other related matters
.
It is understood that Jinling Pharmaceutical’s cancellation of Jinwei Company is based on the overall strategic planning considerations, which will help further integrate the company's resources, improve the company's management efficiency, and reduce management costs
.
It is worth noting that according to incomplete statistics, since this year, at least 20 domestic pharmaceutical companies have announced the sale of shares, subsidiaries, and divestiture of core businesses, including Fosun Pharma, Zhendong Pharmaceutical, and Beike Biotech
.
For example, on August 31, Guangdong Dongyangguang issued an announcement to transfer the company’s holding of no more than 51.
41% equity in Yichang Dongyangyang Yangtze River Pharmaceutical Co.
, Ltd.
After the transfer, Dongyangguang will divest the entire pharmaceutical sector
.
On August 17, Zhendong Pharmaceutical and Shanghai Fanglang signed the "Equity Sale Agreement" and also decided to sell 100% of the wholly-owned subsidiary Langdi Pharmaceuticals to Shanghai Fanglang at a price of 5.
8 billion yuan
.
In this regard, industry analysts believe that behind the frequent subtraction of pharmaceutical companies, it is actually affected by the national policy to encourage the development of innovative drugs, the consistency evaluation of generic drugs, and the large-scale procurement of pharmaceuticals
.
In fact, in recent years, a large number of pharmaceutical companies have been accelerating reform and development by selling shares, subsidiaries, and divesting their core businesses.
.
In this regard, industry analysts believe that under the background of rapid iteration in the pharmaceutical industry, bankruptcies, write-offs, and sales of enterprises have become the norm
.
In the future, in order to make the corporate strategy more focused, more and more companies will sell their assets that are not in line with their own strategic development, so as to focus on the development of the company's main business
.
In general, with a series of industrial upgrades guided by pharmaceutical policies, it is an inevitable event that some companies are left behind and eliminated passively or actively
.
For pharmaceutical companies, under centralized procurement, pharmaceutical profit margins are compressed, prices are squeezed out, and the industry structure has changed
.
If pharmaceutical companies cannot make changes with the changes in the pharmaceutical market, then companies will face elimination
.
In the future, competition in the pharmaceutical market is destined to become more and more fierce, and companies can only occupy a place on the pharmaceutical stage for a long time only if they are both internal and external
.
